SEARCH · Search PubMed
Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.
Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.
The beta-galactosidase (EC 3.2.1.23) activities of wild-type Rhizobium meliloti and its lactose slow-hydrolyzing mutant have been compared. The properties of the enzyme are very different in each strain. These differences allow us to prove that two enzymes with a beta-galactosidase activity can be found in the wild-type whereas only one enzyme remains in the mutant strain.
Alkaline phosphate, catalase and beta-galactosidase activities of Vibrio et tor were decreased after acquisition of resistance towards rifampicin. Zn2+, Mn2+ and EDTA inhibited alkaline phosphatase which is most active with p-nitrophenylphosphate as substrate while Mg2+ was found to suppress alkaline phosphatase activity. Removal of EDTA however, restores the original activity. Rifampicin could not induce mutation of lactose nonfermenting Vibrio el for cells allowing them to grow on lactose as sole carbon source, z-galactosidase which is a constitutive enzyme in this case is repressed by glucose. This repression is overcome by cAMP.
A highly sensitive enzyme-linked immunosorbent assay (ELISA) procedure has been devised for the determination of anti-myelin basic protein antibodies. First, rabbit anti-myelin basic protein (MBP) sera to be assayed were incubated with MBP immobilized on small pieces of silicone rubber. Next, anti-MBP bound specifically to the solid phase was allowed to react either with Fab' of guinea pig anti-rabbit IgG conjugated with beta-D-galactosidase from Escherichia coli or with protein A conjugated with beta-D-galactosidase. The amount of fixed anti-MBP antibodies was assayed by fluorometric determination of the enzyme activity using 4-methylumbelliferyl-beta-D-galactoside as a substrate. The sensitivity of the present assay was at least an order of magnitude higher than the hitherto available radioimmunoassay and ELISA.
The capacity to synthesize alpha-D-galactosidase (EC 3.2.1.22), alpha-D-mannosidase (EC 3.2.1.24), alpha-L-fucosidase (EC 3.2.1.51) and beta-D-acetylglucose aminidase (EC 3.2.1.30) was tested among 100 different cultures of soil microscopic fungi and actinomycetes. Two genera of micromycetes, viz. Scopulariopsis and Aposphaeria, which had not been known as producing alpha-D-galactosidase, were found, as well as several new species of the genus Penicillium: Pen. canescens, Pen. claviforme, Pen. cyclopium, Pen. daleae, Pen. frequentans, Pen. piscarum, Pen. simplicissimu, Pen. thomii.
Different methods for preparing alpha-galactosidase from the culture fluid of the micromycete Cephalosporium sp. 237 were tested. They included precipitation with ethanol, isopropanol, and acetone. Precipitation with two volumes of acetone gave the best results with respect to specific activity (12 units) and yield of the enzyme (78%). Properties of alpha-galactosidase (optimum pH at 5.5, temperature optimum at 40 degrees C. thermolability, etc), when different substrates were used, were examined.
Serum alpha-galactosidase activity was studied in 21 control children, 15 children with Duchenne muscular dystrophy, and in 8 gene carrier mothers. In both the DMD hemi- and the heterozygous groups a significant increase of alpha-galactosidase activity was demonstrated.
beta-Galactosidase was isolated from different organs of the wormwood (Artemisia annua L.). The enzyme activity was found to change during the growth and development of the plant. The maximal activity was revealed in reproductive organs at flowering and fruiting stages. Using ion-exchange chromatography, isoelectric focusing and disc electrophoresis in PAAG, two molecular isoforms of beta-galactosidase were detected. Some physicochemical properties of the enzyme were investigated.
A method for estimating beta-galactosidase activity (beta-D-galactosidase-galactohydrolase, EC 3.2.1.23) with lactose as substrate was developed. The glucose formed as a result of lactose hydrolysis was determined by glucoseoxidase method with potassium ferrocyanide as a substrate-dye. The method is convenient, simple and reproducible, as well as gives an opportunity to characterize the enzyme due to its ability to hydrolyze lactose that is of great value when putting the enzyme into practice.
An enzyme-linked immunosorbent assay (ELISA) system for hepatitis B e antigen (HBeAg) was developed employing beta-D-galactosidase conjugated with antibody to HBeAg (anti-HBe) and using m-maleimidobenzoyl-N-hydroxysuccinimide ester as the coupling reagent. The experimental conditions for quantitative assay of HBeAg were determined. The presence of rheumatoid factor in test sera did not affect the results. This assay system is more sensitive than the micro-Ouchterlony method and as sensitive as radioimmunoassay. The use of beta-D-galactosidase for ELISA in the field of virology is recommended.
The addition of microbial beta-galactosidases directly to milk at mealtime represents a potential "enzyme replacement therapy" for primary lactase deficiency. We used the hydrogen breath test as the index of incomplete carbohydrate absorption to assess the efficacy of two enzymes--one from yeast, Kluyveromyces lactis (LactAid), and the other from the fungus Aspergillus niger (Lactase N)--to assist in the hydrolysis of 18 g of lactose in 360 ml (12 oz) of whole milk when consumed by an adult lactose malabsorber. Graded amounts of Lactase N produced, at best, a 53% relative reduction in breath hydrogen excretion, whereas quantitative elimination of excess hydrogen excretion was produced by 1 and 1.5 g of LactAid. A double-blind, controlled, crossover trial was subsequently performed in 50 healthy, unselected Mexican adults, to whom 360 ml of cow's milk was presented in the three forms in a randomized order: intact milk, prehydrolyzed milk, and milk to which 1 g of LactAid was added immediately before consumption. Among the 25 subjects with incomplete carbohydrate absorption with intact milk, adding enzyme 5-min before consumption produced a 62% reduction in breath hydrogen excretion, and symptoms of intolerance were significantly reduced. The feasibility of effective enzyme replacement therapy with a beta-galactosidase from K. lactis is demonstrated.
A 17-year-old Japanese boy was found to have ataxia, generalized angiokeratomas, skeletal deformities, visual impairment, and macular cherry-red spots, without hepatomegaly, splenomegaly, or renal failure. Laboratory examination disclosed a deficiency of beta-galactosidase as well as of neuraminidase activity in the leukocytes and fibroblasts, while alpha-galactosidase and alpha-L-fucosidase activities were normal. On electron microscopic examination, numerous cytoplasmic vacuoles containing flocculated material were found in the vascular endothelial cells, histiocytes, perineurial cells, and Schwann's cells.
A partial synthesis of a structural gene for beta-galactosidase and construction of a series of pLZ plasmids for quantitative study of E. coli promoters are reported. The gene was assembled of two short synthetic DNAs and of a 3000 bp long EcoRI fragment (comprising the lacZ sequence 16-3013) isolated from plasmid p198/1 of B. Gronenborn. Among the plasmids constructed, pLZ4 is a promoter-probe vector that contains the semi-synthetic gene fused with a synthetic Shine-Dalgarno sequence and preceded by unique EcoRI and KpnI cleavage sites. On cloning a promoter into these sites, its signal strength in vivo could easily be measured by assaying beta-galactosidase activity. The use of pLZ4 vector was demonstrated by quantifying the effect of T7 early promoters A1 and A2, the latter being found 4,5 times more active under the conditions employed.
A new strain of Escherichia freundii was isolated from human feces. Compared with the previous strain (Kitamikado, M., and Ueno, R. (1970) Bull. Jpn. Soc. Sci. Fish. 36, 1175-1180), this strain releases comparable levels of endo-beta-galactosidase with lower levels of exoglycosidases in the culture medium containing 0.3% of keratan sulfate. Endo-beta-galactosidase was purified by an improved purification procedure involving Amicon H1P10 hollow fiber filtration, QAE-Sephadex A-50, and CM-Sephadex C-50 chromatographies. The purified enzyme is completely free from proteases and exoglycosidases. The general properties of this enzyme are: molecular weight, 28,000; optimal pH, 5.5 TO 5.8; PI, pH 8.0. This enzyme hydrolyzed keratan sulfates isolated from different sources to produce 6-O-sulfo-GlcNAc beta1 leads to 3Gal as the major product. In addition, the specificity of this enzyme toward various glycoconjugates was also studied.
beta-Galactosidase from Alternaria tenius was purified to homogeneity from the cultural fluid using acetone precipitation, ion-exchange chromatography on DEAE-cellulose, adsorption on hydroxylapatite and affinity chromatography on N-(beta-D-galactopyranosyl-thiocarbamoyl)-beta-aminocaproyl-AN-Sepharose 4B. The enzyme homogeneity was demonstrated by ultracentrifugation and polyacrylamide gel electrophoresis with SDS or without it. The specific activity of the homogeneous enzyme is 160 u. per mg of protein; mol. weight as determined by various methods is 142 000-176 000, pI = 4.6, temperature optimum is 60-65 degrees, pH optima for o-nitrophenyl-beta-D-galactopyranoside (o-NPG) and lactose are 3.8--4.4 and 3.6--4.8, respectively. The Km values for o-NPG and lactose are 0.21 . 10(-3) and 6.57 . 10-3 M, respectively. The enzyme is a glycoprotein and contains up to 30% of carbohydrates. EDTA and pCMB have no effect on the beta-galactosidase activity. Galactose acts as a competitive inhibitor, while glucose has no inhibiting effect on the enzyme activity.
Activation of a defective Escherichia coli beta-D-galactosidase by specific activating antibody is inhibited competitively by a molecule with immunoglobulin properties but devoid of activating capacity. This molecule is found in the serum of nonimmunized rabbits and is no longer detectable after beta-D-galactosidase administration, but can be demonstrated in rabbits injected with antigens other than the enzyme. The data show that the inhibitory molecule recognizes and interacts specifically with the activating epitope of the activatable enzyme and that, although unable to activate the latter, it competes with the activating antibody and inhibits activation.
Two genetic loci, Ir-Z1 and ir-Z2, controlling the immune response to adjuvant-free bacterial beta-D-galactosidase (Z) are present in inbred mouse strains SJL/J and CE/J, respectively. Each locus segregates as a single, autosomal gene: Ir-Z1 as dominant and ir-Z2 as recessive. The response is characterized by production of activating and precipitating IgG. Maximal levels of circulating IgG occur between 16 and 20 days after immunization with a single, 50-microgram dose of enzyme. Failure of proteins other than Z to elicit an immune response indicates that the Ir-Z control is specific for determinant(s) of this enzyme. The immunogenicity of beta-D-galactosidase preparations cannot be attributed to either the catalytic activity of the enzyme or adjuvant contamination. Non-responder mice acquire immunologic memory without detectable increase in circulating specific IgG under the same conditions that elicit antibody production in responder strains.
GM1-gangliosidosis is a lysosomal storage disorder caused by deficiency of acid beta-galactosidase (GLB1). We report five new beta-galactosidase gene mutations in nine Italian patients and one fetus, segregating in seven unrelated families. Six of the eight patients with the infantile, severe form of the disease presented cardiac involvement, a feature rarely associated with GM1-gangliosidosis. Molecular analysis of the patients' RNA and DNA identified two new RNA splicing defects, three new and three previously described amino acid substitutions. Interestingly, all patients with cardiac involvement were homozygous for one of these mutations: R59H, Y591C, Y591N, or IVS14-2A>G. In contrast, all other patients were compound heterozygous for one of the following mutations: R201H, R482H, G579D, IVS8+2T>C. Although we could not directly correlate the presence of cardiac abnormalities with specific genetic lesions, the mutations identified in patients with cardiomyopathy fell in the GLB1 cDNA region common to the lysosomal enzyme and the Hbeta-Gal-related protein, also known as the elastin binding protein (EBP). Consequently, both molecules are affected by the mutations, and they may contribute differently to the occurrence of specific clinical manifestations.
beta-Galactosidase was incubated for 60 min with the fluorogenic substrate resorufin-beta-D-galactopyranoside, which is converted by the action of the enzyme into resorufin and galactose. A 160 pL aliquot of reaction mixture was analyzed by capillary electrophoresis utilizing laser-induced fluorescence detection. Based on the detection of the resorufin formed, the limit of detection of beta-galactosidase was 1.5 x 10(-15) M or 900 molecules of enzyme in a 1 microL sample.